ArborGen reports $2.1m loss, sales down 3%

ArborGen has reported a net loss after tax of $2.1 million for the first half of the 2025 financial year.

This compares to a loss of $100,000 in the same period last year.

The company's sales revenue for the half year was down 3% to $12.8m.

ArborGen said the decrease in sales revenue was a result of the challenging market, particularly in the US South, which remains at the low end of the cycle.

The company said its long-term focus on advanced genetics has been beneficial, as it has been able to achieve superior prices and margins.

ArborGen's chief executive, Justin Birch, said Brazil continues to be an exciting growth opportunity and the company is expanding its production capacity there.

The company expects full-year group sales volumes to be down on last year, with a corresponding impact on earnings.

Adjusted US GAAP ebitda, excluding one-off and unusual items, is expected to be between $8.5m and $10m.